NCCN Guidelines for Patients® | Myelodysplastic Syndromes
41 NCCN Guidelines for Patients ® : Myelodysplastic Syndromes, 2018 5 Treatment guide Treatment options Part 5 is a guide through the treatment options for people with MDS. This information is taken from the treatment guidelines written by NCCN experts of MDS. These treatment guidelines list options for people with MDS in general. Thus, your doctors may suggest other treatment for you based on your health and personal wishes. Fully discuss your treatment options with your doctor. Treatment options There are multiple treatment options for MDS. Treatment options that are best for you depend on a number of factors. This includes the features of the cancer, such as the MDS subtype and risk score, as well as your age and health status. The treatment options in Part 5 are organized by MDS risk groups and symptoms. The timing, intensity, and goal of treatment differs depending on the risk group. To plan treatment, doctors put risk groups into two categories: lower-risk MDS and higher-risk MDS. Lower-risk MDS includes the following risk groups: IPSS Low and Intermediate-1; IPSS-R Very Low, Low, and Intermediate; and WPSS Very Low, Low, and Intermediate. Higher-risk MDS includes the following risk groups: IPSS Intermediate-2 and High; IPSS-R Intermediate, High, and Very High; and WPSS High and Very High. Lower-risk MDS is more likely to grow slowly and may not progress to AML for a long time. Thus, low-intensity treatments are used first. The goal of treatment for lower-risk MDS is to improve blood cell counts, lessen the need for blood transfusions, and improve quality of life. Higher-risk MDS is more likely to grow faster and progress to AML in a shorter amount of time. Thus, high-intensity treatments are often tried first. The goal of treatment for higher-risk MDS is to slow or stop MDS progression to AML and help patients live longer.